Affymetrix Looks Forward, Envisions Expansion of Microarray Product Line | GenomeWeb

A year ago this week, Affymetrix CEO Steve Fodor and president Susan Siegel warned investors in a conference call that revenues for the second quarter would fall sharply short of Wall Street’s modest expectations. Customer confidence in the company had been seriously shaken following its disclosure last March that its mouse chips had contained defective oligos, and as a result, Affymetrix was seeing what Siegel called “erratic ordering patterns” for its arrays: in other words, pharma wasn’t buying.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.